Atossa Therapeutics, Inc. (ATOS) Stock Score, Valuation & Financial Research

Atossa Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ATOS

Atossa Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.45. These figures are a research snapshot, not a buy or sell recommendation.

What Atossa Therapeutics, Inc. does

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Atossa Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and warrant exercises to fund the research and development of proprietary pharmaceutical candidates, specifically (Z)-endoxifen, for oncology and other therapeutic areas.

Products and services

  • The company is developing (Z)-endoxifen, a proprietary drug candidate intended for the prevention and treatment of breast cancer and other therapeutic indications, which does not require first-pass metabolism.

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party CROs and CMOs for clinical trial management, drug development services, and the manufacturing of drug candidates for clinical use. Specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Proprietary (Z)-endoxifen drug candidate with established patent protection Source

Business risks and research considerations

  • History of operating losses and dependence on future capital raises Source
  • Clinical trial failure or delays in regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ATOS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.45
Market capitalization:
24.44M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -37.71M
Free cash flow:
USD -29.79M
Cash:
USD 26.09M
Total debt:
USD 0.00
EPS:
USD -4.34

What stands out

  • Free cash flow is USD -29.79M, negative for the stored period.
  • The balance sheet shows USD 26.09M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 26.09M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ATOS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ATOS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ATOS likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ATOS to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of ATOS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research ATOS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.